Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 4/17/2018 |
| Start Date: | August 1, 2016 |
| End Date: | November 28, 2017 |
A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults
The purpose of this study is to compare the efficacy and safety of BCT197 when added on to
standard of care in adult subjects with acute respiratory exacerbations of chronic
obstructive pulmonary disease requiring hospitalization. Additionally, the study will
characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the
study will be 26 weeks. Subjects will receive study treatment administration over a period of
5 days after randomization. It is expected that approximately 255 subjects will complete the
study and follow-up.
standard of care in adult subjects with acute respiratory exacerbations of chronic
obstructive pulmonary disease requiring hospitalization. Additionally, the study will
characterize the pharmacokinetics of BCT197 in adults with COPD. The total duration of the
study will be 26 weeks. Subjects will receive study treatment administration over a period of
5 days after randomization. It is expected that approximately 255 subjects will complete the
study and follow-up.
Inclusion Criteria:
- Male and female adults
- Presence of an active exacerbation of the ongoing COPD requiring hospitalization for
treatment
- Subjects with a documented diagnosis of COPD C or D
- Current smokers or ex-smokers
- A documented history of at least one moderate or severe COPD exacerbation in the 12
months preceding the Screening Visit that required antibiotics and/or systemic
corticosteroid.
- Current regular treatment for COPD (for at least 2 months prior to the Screening
Visit.
Exclusion Criteria:
- Age less than 40 years old
- Current diagnosis of asthma
- Subjects who have already completed treatment for the current exacerbation of COPD
- Subjects currently requiring intensive care unit (ICU) and/or mechanical ventilation
- Received a course of PDE4, p38 or PDE3/4 inhibitors within their respective defined
washout periods.
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials